New triple-action diabetes jab delivers impressive blood sugar and weight-loss results

A new triple hormone receptor agonist for type 2 diabetes could lower blood pressure and body weight. The clinical results achieved after 40 weeks showed that patients taking weekly retatrutide injections lost more than four times as much weight as patients taking the placebo. 

Most importantly, the average drop in long-term blood sugar was twice than that of the placebo group. The three distinct gut hormones that control appetite, blood sugar, and metabolism are GLP-1, GIP, and glucagon.

Unlike older drugs, retatrutide activates the glucagon receptor which actively increases the body’s energy expenditure. Following is the comparison with other diabetic medication:

It has been observed that Ozempic&Wegovy only target one pathway (GLP-1) to suppress appetite. On the other hand, Monjaro targets two pathways to manage blood sugar.

The study trials, published in The Lancet, made experimentation by 930 adults with Type 2 diabetes. Patients were randomly assigned to a placebo or one of three retatrutide doses such as 4mg, 9mg or 12mg.

Notably, all participants had a BMI of at least 23 and possessed poorly controlled blood sugar levels. These findings align with earlier results from Eli Lilly suggesting that retatrutide was highly effective in weight reduction in patients with obesity.

Dr Kath McCullough at the Royal College of Physicians said: “For many people living with diabetes and obesity, treatments like this could be genuinely life-changing,” she said.

“However, medications are not a silver bullet. While they are proving to be effective, the long-term goal must be to prevent people from needing them in the first place.”

Dr Lucy Chambers, the head of research impact and communications at Diabetes UK, said: “These encouraging findings show that this new class of drug for type 2 diabetes could deliver dual benefits for both weight loss and blood-sugar management. We look forward to further research to understand its long-term effects and how it compares to treatments already available on the NHS.”